NHS Dudley Health Economy Medicines Formulary
Home > 5 Infections > 5.3 Antiviral drugs > 5.3.3 Viral hepatitis > 5.3.3.2 Chronic hepatitis C > Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C - NICE TAG TA365

Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C - NICE TAG TA365

1.1 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir is recommended, within its marketing authorisation, as an option for treating genotype 1 or 4 chronic hepatitis C in adults, as specified in table 1, only if the company provides ombitasvir–paritaprevir–ritonavir and dasabuvir at the same price or lower than that agreed with the Commercial Medicines Unit.

Table 1 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating adults with chronic hepatitis C

HCV genotype, liver disease stage

Treatment

Duration (weeks)

Recommendation according to treatment history

Untreated

Treated

1a, without cirrhosis

Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin

12

Recommended

1a, with compensated cirrhosis

Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin

24

Recommended

1b, without cirrhosis

Ombitasvir–paritaprevir–ritonavir with dasabuvir

12

Recommended

1b, with compensated cirrhosis

Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin

12

Recommended

4, without cirrhosis

Ombitasvir–paritaprevir–ritonavir with ribavirin

12

Recommended

4, with compensated cirrhosis

Ombitasvir–paritaprevir–ritonavir with ribavirin

24

Recommended

Abbreviation: HCV, hepatitis C virus.

Treated – the person's hepatitis C has not adequately responded to interferon‑based treatment.

1.2 It is recommended that the decision to treat and prescribing decisions are made by multidisciplinary teams in the operational delivery networks put in place by NHS England, to prioritise treatment for people with the highest unmet clinical need.

 

https://www.nice.org.uk/guidance/ta365

Site by Devopa
© Copyright 2019 NHS. All rights reserved.